MHRA Chair outlines innovation and safety priorities for five-year strategy

What Changed

MHRA Chair Professor Anthony Harnden has outlined the priorities shaping the agency’s five-year strategy in a news story dated 9 October 2026. Closing its strategy blog series, the article describes the intended direction of regulatory development rather than announcing a new medical-device rule.

Harnden says contributions from academia, industry and the wider health system challenged and strengthened the agency’s thinking. The central themes are UK-wide connections, proportionate support for innovation, patient safety and organisational capability.

Who Is Affected

The discussion is relevant to medical-device and AI-enabled technology developers, researchers, health systems, healthcare professionals and patients. It does not establish new obligations for a defined product group.

The article highlights Scotland’s clinical research infrastructure, Northern Ireland’s distinctive regulatory position and Wales’s connected health and care system. The MHRA aims to strengthen partnerships with devolved governments and regional stakeholders while maintaining consistent standards across different contexts.

Regulatory and Technical Implications

Advanced therapies and AI-enabled technologies illustrate the need for frameworks that are robust without being rigid. Harnden identifies evolving evidence assessment, earlier engagement with innovators and balancing opportunity against risk as elements of a patient-centred approach.

For safety surveillance, the ambition is to use data more intelligently, connect information across sources and identify risks earlier. Understanding which patient groups face greater risk could support earlier, more targeted action. Clear communication of emerging safety issues and uncertainty, alongside recognition of patient risk preferences, is presented as essential to public trust.

Manufacturer Actions

The article specifies no mandatory submission, technical documentation update or new reporting step for manufacturers. Its references to early engagement, evidence assessment and data-driven surveillance should be understood as strategic priorities, not detailed compliance instructions.

Harnden also links delivery to investment in staff skills, leadership and organisational culture. No separate manufacturer implementation plan accompanies the supplied article.

Confirmed Dates

The source article was published on 9 October 2026. Although it refers to a five-year strategy, it does not specify the strategy’s exact start and end dates or a manufacturer compliance deadline.

Official Source

MHRA’s closing strategy blog contribution by Chair Professor Anthony Harnden, published on GOV.UK.

https://www.gov.uk/government/news/mhra-chair-professor-anthony-harnden-bringing-our-strategy-to-life-listening-learning-and-looking-ahead